User:Tkadm30/Notebook/Aripiprazole: Difference between revisions
From OpenWetWare
< User:Tkadm30 | Notebook
m (Yar moved page User:Etienne Robillard/Notebook/Aripiprazole to User:Tkadm30/Notebook/Aripiprazole: Automatically moved page while renaming the user "Etienne Robillard" to "Tkadm30") |
|||
| (9 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
===Synopsis=== | |||
Phenylpiperazine derivative. | |||
===Functional selectivity of aripiprazole at D2 receptors=== | ===Functional selectivity of aripiprazole at D2 receptors=== | ||
* [https://www.ncbi.nlm.nih.gov/pubmed/16554739 Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.] | * [https://www.ncbi.nlm.nih.gov/pubmed/16554739 Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.] | ||
| Line 11: | Line 15: | ||
* [http://www.komci.org/GSResult.php?RID=0195CPN%2F2011.9.1.36&DT=6 Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex] | * [http://www.komci.org/GSResult.php?RID=0195CPN%2F2011.9.1.36&DT=6 Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex] | ||
* https://www.mrnice.nl/forum/9-patients-forum/15829-aripiprazole-thc-interactions.html | * https://www.mrnice.nl/forum/9-patients-forum/15829-aripiprazole-thc-interactions.html | ||
===Aripiprazole-mediated gene expression=== | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602118/ Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/17868501/ Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex.] | |||
===Side effects=== | ===Side effects=== | ||
| Line 18: | Line 25: | ||
* Insomnia | * Insomnia | ||
* Tardive dyskinesia | * Tardive dyskinesia | ||
* Racing thoughts? | * Racing thoughts | ||
* [https://www.thenakedscientists.com/forum/index.php?topic=70477 Hyperdreaming] | |||
* Hyperprolactinemia | |||
===Notes=== | ===Notes=== | ||
Latest revision as of 14:57, 2 October 2018
Synopsis
Phenylpiperazine derivative.
Functional selectivity of aripiprazole at D2 receptors
- Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
- Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures.
- Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
- Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
- Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats
- Chronic administration of aripiprazole activates GSK3β-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats
Aripiprazole/THC interactions
- Aripiprazole-CB1 activation may increase functional selectivity at dopamine D2 receptors? (Reference needed)
- Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex
- https://www.mrnice.nl/forum/9-patients-forum/15829-aripiprazole-thc-interactions.html
Aripiprazole-mediated gene expression
- Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.
- Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex.
Side effects
- Worsened hypertension control induced by aripiprazole
- Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
- Akathisia
- Insomnia
- Tardive dyskinesia
- Racing thoughts
- Hyperdreaming
- Hyperprolactinemia
Notes
- Is Aripiprazole a selective FAAH inhibitor?
